These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25702542)

  • 1. Authors' reply.
    Lainas TG; Kolibianakis EM
    BJOG; 2015 Mar; 122(4):585-6. PubMed ID: 25702542
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
    Ko HS; Kim N; Park YG
    BJOG; 2015 Mar; 122(4):585. PubMed ID: 25702543
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    BJOG; 2014 Jun; 121(7):848-55. PubMed ID: 24621101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
    Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
    Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study.
    Giles J; Requena A; García-Velasco JA; Pacheco A; Pellicer J; Pellicer A
    Fertil Steril; 2009 Apr; 91(4 Suppl):1366-9. PubMed ID: 18692821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pituitary adenoma secreting follicle-stimulating hormone with ovarian hyperstimulation: treatment using a gonadotropin-releasing hormone antagonist.
    Garmes HM; Grassiotto OR; Fernandes YB; Queiroz Lde S; Vassalo J; de Oliveira DM; Benetti-Pinto CL
    Fertil Steril; 2012 Jan; 97(1):231-4. PubMed ID: 22118994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?
    Fauser BC; Devroey P
    Fertil Steril; 2005 Jun; 83(6):1607-11. PubMed ID: 15950626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of ovarian hyperstimulation syndrome using gonadotropin releasing hormone antagonist: a pilot study.
    Hosseini MA; Mahdavi A; Aleyasin A; Safdarian L; Bahmaee F
    Gynecol Endocrinol; 2012 Nov; 28(11):853-5. PubMed ID: 22697477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High levels of soluble vascular endothelial growth factor receptor 1/sFlt1 and low levels of vascular endothelial growth factor in follicular fluid on the day of oocyte retrieval correlate with ovarian hyperstimulation syndrom regardless of the stimulation protocol.
    Jakimiuk AJ; Nowicka MA; Zagozda M; Koziol K; Lewandowski P; Issat T
    J Physiol Pharmacol; 2017 Jun; 68(3):477-484. PubMed ID: 28820403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The addition of GnRH antagonists in intrauterine insemination cycles with mild ovarian hyperstimulation does not increase live birth rates--a randomized, double-blinded, placebo-controlled trial.
    Cantineau AE; Cohlen BJ; Klip H; Heineman MJ;
    Hum Reprod; 2011 May; 26(5):1104-11. PubMed ID: 21339196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pulsatile gonadotropin releasing hormone treatment following previous ovarian hyperstimulation].
    Koloszár S; Bártfai G
    Orv Hetil; 1993 Jul; 134(28):1521-3. PubMed ID: 8341530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of coasting in patients undergoing controlled ovarian stimulation with the gonadotropin-releasing hormone antagonist cetrorelix.
    Bahceci M; Ulug U; Tosun S; Erden HF; Bayazit N
    Fertil Steril; 2006 May; 85(5):1523-5. PubMed ID: 16566935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing ovarian hyperstimulation with gonadotropin-releasing hormone agonist trigger: is anything perfect?
    Filicori M
    Fertil Steril; 2014 Apr; 101(4):936-7. PubMed ID: 24613536
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention and management of ovarian hyperstimulation syndrome.
    Chen CD; Chen SU; Yang YS
    Best Pract Res Clin Obstet Gynaecol; 2012 Dec; 26(6):817-27. PubMed ID: 22647872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome.
    Gustofson RL; Larsen FW; Bush MR; Segars JH
    Fertil Steril; 2006 Jan; 85(1):251-4. PubMed ID: 16412770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
    Mai Q; Hu X; Yang G; Luo Y; Huang K; Yuan Y; Zhou C
    Am J Obstet Gynecol; 2017 Jan; 216(1):42.e1-42.e10. PubMed ID: 27555316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist.
    Taskin MI; Topcu O; Yay A; Erken G; Balcioğlu E; Adali E; Hismiogulları AA
    Gynecol Endocrinol; 2015; 31(12):949-54. PubMed ID: 26369707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
    Pereira N; Lekovich JP; Kligman I; Rosenwaks Z
    Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analogues agonists and antagonists: what is their role outside of fertilization in vitro?].
    Antoine JM; Merviel P; Alvarez S; Mandelbaum J; Salat-Baroux J; Uzan S
    Gynecol Obstet Fertil; 2000 Oct; 28(10):757-9. PubMed ID: 11244639
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.